Eagle Daily Investor

The Red-Hot Sector Beating the S&P 500 by Three to One

Biotechnology is a high-octane sector where fortunes are made and lost quickly.

That’s because investing in biotech stocks is a lot like investing in small-cap mining stocks or Silicon Valley start-ups. You have to kiss a lot of investment frogs before you find your “Prince” Google or Facebook.

Biotechnology has had four massive, triple-digit percentage gain bull markets since the 1980s. The two biggest ones were, first, in the early 1990s, when biotech stocks soared almost 10-fold. The second came later during the dot-com boom, when the Nasdaq Biotechnology Index rose 457% from the end of August 1998 to the end of February 2000. But having been burned by dozens of investments that “went south,” investors never regained the enthusiasm for biotech they once had in the 1990s.

That said, biotechnology has already clocked some impressive gains this year, with the Nasdaq Biotech index up 41.91% year-to-date.

And the biotech sector, as represented by the iShares Nasdaq Biotechnology (IBB), outperformed the S&P 500 over the past five years by just about three to one.

Global Guru

As one investor put it, “If you catch just one biotech bull market in your lifetime, you may never have to work again.”

Biotechnology: Get Ready For Bull Market #5

I believe we’re overdue for another triple-digit percentage run in biotech stocks…

And here’s why…

Big Pharma is saddled by two problems: the rise of generics and finding new drugs.

First, since the mid-1980s, generics have been able to move into Big Pharma’s territory once patents expire. Today, Big Pharma has only about 20 years to earn as much as it can before it is undercut by generic firms.

Second, first-generation medicines, such as antibiotics and beta-blockers to treat high blood pressure, were the low-hanging fruit of the industry. Diseases of the young — like polio — were relatively easy to defeat. But diseases of old age — like cancer and heart problems — are a much tougher and a more expensive nut to crack.

New products for an aging baby-boomer population and expansion into emerging markets mean that the sector is poised for fast growth for the foreseeable future.

Here are three reasons why I think biotech is at the start of if its fifth massive, triple-digit percentage bull market.

1. Takeover Activity

The strategy of Big Pharma is being driven by one fundamental dynamic: it’s much cheaper for a large company to acquire a potential “blockbuster” through a buyout rather than spend years on research and plowing through Food and Drug Administration (FDA) bureaucracy. And these takeovers of smaller biotech stocks — are often at huge premiums to existing stock prices.

2. New Product Pipeline

Biotech companies often invest heavily in research and development of products. But like the portfolio of a venture capitalist in Silicon Valley, more drugs end up being “Pets.com” than the next “Google.” That also means that investors rely on a few “home-run” products to make money. In July 2009, Human Genome Sciences surged more than 450% in a week after its lupus drug, Benlysta, showed late-stage success in a clinical trial.

3. Regulatory Environment

Patent protection and intellectual property rights are at the core of the biotech industry. Any change in the laws could change the outlook for the entire industry overnight. Regulators are also imposing ever more strict, and costly, testing procedures. Today, it takes 15 years to get a drug approved. A global launch costs $2 billion — up from $150 million 20 years ago.

But things may be changing. There also has been an improving trend for FDA first-cycle approvals and a rise in the rate of new drug approvals for rare diseases, helping to boost investor sentiment toward the biotechnology sector.

How to Play the Biotech Investment Game

There are two ways you can play the biotech investment game.

First, focus like a laser in the sector and bet big on a single stock. Then wait for your ship to come in.

Second, buy a diversified exchange-traded fund (ETF) that invests across the range of “lottery tickets.”

Picking one winner is a tough game to play. Biotechnology is an industry of “one hit wonders.” Just because a company has developed one successful biotech drug doesn’t mean it has any better chance of developing another.

That’s why I think the best way to invest in biotech is through a biotechnology ETF, which gives you broad exposure to the sector, while limiting your specific, company risk.

Triple-Digit Percentage Gains in Biotech in Just Three Weeks

A recent recommendation in my Triple Digit Trader service was a bullish bet on the biotech industry through the ProShares Ultra Nasdaq Biotechnology (BIB). Its performance corresponds to twice (2x) the daily performance of the underlying Nasdaq Biotechnology Index. BIB holds stakes in 10 of the biggest biotech companies. Its top three holdings — Gilead Sciences Inc. (GILD), Regeneron Pharmaceuticals, Inc. (REGN) and Amgen Inc. (AMGN) — together account about 25% of the fund’s assets.

What gives the ProShares Ultra Nasdaq Biotechnology (BIB) its kick in a rising market is its leverage. Just look at how BIB’s leveraged performance compares to un-leveraged big brother, iShares Nasdaq Biotechnology (IBB), over the past six months.

Global Guru

A bet on BIB generated twice the returns of iShares Nasdaq Biotechnology (IBB). That said, this return did come at the price of higher volatility.

I recommended ProShares Ultra Nasdaq Biotechnology (BIB) on June 27, as well as related December $180 call options in the iShares Nasdaq Biotechnology (IBB). By July 12, my subscribers booked 78.27% gains on the options.

Four days later, these same options were up 115.75%, and my subscribers sold the ProShares Ultra Nasdaq Biotechnology (BIB) for a 20% gain soon thereafter.

My current view?

With its 2x leverage, I believe the ProShares Ultra Nasdaq Biotechnology (BIB) could rally as much as 30% over the coming months.

To read my e-letter from last week, please click here. I also invite you to comment about my column in the space provided below.

P.S. Join me for the San Francisco Money Show, Aug. 15-17, at the San Francisco Marriott Marquis. There is no charge for this conference, but you do need to register. Call 1-800/970-4355, and mention code #031736.

About Nicholas Vardy

Nicholas Vardy is currently Editor of The Global Guru, a free weekly e-newsletter, and a monthly investment newsletter, The Alpha Investor Letter, which provides longer-term global investments. He also writes two weekly trading services, Triple Digit Trader and Bull Market Alert, which focus on making short-term profits in the hottest markets in the world. A former mutual fund money manager, he is also chief investment officer of Global Guru Capital LLC, where he manages separate accounts for high net worth individuals. A graduate of Stanford University and the Harvard University Law School, he has a unique background that has proven his knack for making money in different markets around the world. He also is a chartered financial analyst.

View all posts by Nicholas Vardy →

  • NASDAQ Composite • 4148.338 ▲21.372(0.52%)
  • S&P 500 • 1878.61 ▲3.22(0.17%)
  • GCZ13.CMX • 0.00 (N/A)
  • • 0.00 0.00(0.00%)
  • Russell 2000 • 1144.352 ▼2.728(0.24%)

Follow us on: